| ID | 1189 |
| Name of the vaccine | SF2a-TT15 |
| Microbe | Bacteria |
| Disease name | Bacillary Dysentery (Shigellosis) |
| Name of bacteria | Shigella genus |
| Type of vaccine | Conjugate |
| Nucleic acid content | DNA |
| Age | 18 to 45 years |
| Description of the vaccine | Monovalent Synthetic Carbohydrate-based. |
| Name of the manufacturer | University of Maryland, Baltimore |
| Name of the manufacturing country | United States |
| Year of manufacture | 2022 |
| Clinical Phase status | Clinical - Suspended |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Two doses, gap of 4 weeks. |
| Mechanism of action | Serum SF2a-specific IgG antibodies. |
| Route of administration | Intramuscular |
| Indications | Prevention of Shigella infection. |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 33186516 |
| Clinical trial number | NCT04078022 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|